Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation

The Lancet Neurology

Volumn 11, Issue 12, 2012, Pages 1066-1081

  Alberts, Mark J ^a,b   Eikelboom, John W ^c   Hankey, Graeme J ^d,e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d ROYAL PERTH HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; APIXABAN; DABIGATRAN ETEXILATE; HEPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CEREBROVASCULAR ACCIDENT; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROPENSITY SCORE; REVIEW; RISK ASSESSMENT; STROKE PATIENT; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HEART VALVES; HEMORRHAGE; HUMANS; STROKE; TREATMENT OUTCOME;

EID: 84869114866     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70258-2     Document Type: Review

References (141)

1. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011, 57:e101-e198.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151. for the RE-LY Steering Committee and Investigators.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L Newly identified events in the RE-LY trial (letter to the editor). N Engl J Med 2010, 363:1875-1876. for the Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators.
4. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891. for the ROCKET AF Investigators.
5. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992. for the ARISTOTLE Committees and Investigators.
6. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817. for the AVERROES Steering Committee and Investigators.
7. Lip GY, Brechin CM, Lane DA The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012, published online March 29. 10.1378/chest.11-2888.
8. Fitzmaurice DA, Hobbs FDR, Jowett S, et al. Screening versus routine practice for detection of atrial fibrillation in people aged 65 or over: cluster randomised controlled trial. BMJ 2007, 335:383-386.
9. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults-national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001, 285:2370-2375.
10. DeWilde S, Carey IM, Emmas C, Richards N, Cook DG Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006, 92:1064-1070.
11. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmstead County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114:119-125.
12. Wolf PA, Abbott RD, Kannel WB Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991, 22:983-988.
13. Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 2004, 94:889-894.
14. Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol 2007, 49:986-992.
15. Conen D, Chae CU, Glynn RJ, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA 2011, 305:2080-2087.
16. Gattellari M, Boumas C, Aitken R, Worthington JM Outcomes for patients with ischaemic stroke and atrial fibrillation: the PRISM study (a Program of Research Informing Stroke Management). Cerebrovasc Dis 2011, 32:370-382.
17. Miyasaka Y, Barnes ME, Gersh BJ, et al. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. Stroke 2005, 36:2362-2366.
18. Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA Atrial fibrillation and stroke in the general Medicare population: a 10 year perspective (1992-2002). Stroke 2006, 37:1969-1974.
19. The atlas of heart disease and stroke, part three. The burden: global burden of stroke 2004, WHO, World Health Organization, Geneva.
20. Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Prostran MS, Lip GY Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol 2012, 5:319-326.
21. Potpara TS, Stankovic GR, Beleslin BD, et al. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation-implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. Chest 2012, 141:339-347.
22. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007, 69:546-554. The Stroke Risk in Atrial Fibrillation Working Group.
23. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008, 39:1901-1910. The Stroke Risk in Atrial Fibrillation Working Group.
24. Hughes M, Lip GY Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008, 99:295-304.
25. Hart RG, Pearce LA Current status of stroke risk stratification in patients with atrial fibrillation. Stroke 2009, 40:2607-2610.
26. Cook NR Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 2008, 54:17-23.
27. Tripepi G, Jager KJ, Dekker FW, Zoccali C Statistical methods for the assessment of prognostic biomarkers (part 1): discrimination. Nephrol Dial Transplant 2010, 25:1399-1401.
28. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ Validation of clinical classification schemes for predicting stroke: results of the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
29. Karthikeyan G, Eikelboom JW The CHADS2 score for stroke risk stratification in atrial fibrillation-friend or foe?. Thromb Haemost 2010, 104:45-48.
30. Lip GYH Can we predict stroke in atrial fibrillation?. Clin Cardiol 2012, 35(suppl 1):21-27.
31. Hobbs FDR, Roalfe AK, Lip GYH, Fletcher K, Fitzmaurice DA, Mant J Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ 2011, 342:d3653. for the Birmingham Atrial Fibrillation in the Aged Investigators and Midland Research Practices Consortium Network.
32. Poli D, Lip GY, Antonucci E, Grifoni E, Lane D Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol 2011, 22:25-30.
33. Lip GYH, Lane D, van Walraven C, Hart RG The additive role of plasma von Willebrand factor levels to clinical factors for risk stratification in patients with atrial fibrillation. Stroke 2006, 37:2294-2300.
34. Hylek EM, Frison L, Henault LE, Cupples A Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. Stroke 2008, 39:3009-3014.
35. Baruch L, Gage BF, Horrow J, et al. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?. Stroke 2007, 38:2459-2463.
36. Lip GY, Frison L, Halperin JL, Lane DA Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010, 41:2731-2738.
37. Keogh C, Wallace E, Dillon C, Dimitrov BD, Fahey T Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke: a systematic review and meta-analysis. Thromb Haemost 2011, 106:528-538.
38. Lip GY, Pisters R, Lane DA, Crijns HJ Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010, 137:263-272. NieuwlaatR.
39. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: a nationwide cohort study. BMJ 2011, 342:d124.
40. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012, 107:172-179.
41. van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY A comparison of risk stratification schema for stroke in 79 884 atrial fibrillation patients in general practice. J Thromb Haemost 2011, 9:39-48.
42. Friberg L, Rosenqvist M, Lip GY Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012, 33:1500-1510.
43. Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 2012, 307:1952-1958.
44. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006, 151:713-719.
45. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest 2010, 138:1093-1100.
46. Lip GY, Frison L, Halperin JL, Lane DA Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011, 57:173-180.
47. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) Study. J Am Coll Cardiol 2012, 60:861-867.
48. Roldán V, Marín F, Fernández H, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a 'real world' anticoagulated atrial fibrillation population. Chest 2012, published online June 21. 10.1378/chest.12-0608.
49. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31:2329-2369. for the European Heart Rhythm Association and European Association for Cardio-Thoracic Surgery.
50. Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011, 13:723-746.
51. Friberg L, Rosenqvist M, Lip GY Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012, 125:2298-2307.
52. Connolly SJ, Eikelboom JW, Ng J, et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011, 155:579-586. and the ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators.
53. Oldgren J, Alings M, Darius H, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011, 155:660-667. for the RE-LY Investigators.
54. McGrath ER, Kapral MK, Fang J, et al. Which risk factors are more associated with ischemic stroke than intracerebral hemorrhage in patients with atrial fibrillation?. Stroke 2012, published online May 22. 10.1161/STROKEAHA.112.654145.
55. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007, 50:309-315.
56. Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008, 83:312-321.
57. Shen AY, Chen W, Yao JF, Brar SS, Wang X, Go AS Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. CNS Drugs 2008, 22:815-825.
58. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012, 367:625-635.
59. Gorter JW Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors: Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999, 53:1319-1327.
60. Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009, 8:165-174. for the Microbleed Study Group.
61. Orken DN, Kenangil G, Uysal E, Forta H Cerebral microbleeds in ischemic stroke patients on warfarin treatment. Stroke 2009, 40:3638-3640.
62. Paciaroni M, Agnelli G, Micheli S, Caso V Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007, 38:423-430.
63. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
64. Aguilar MI, Hart R Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005, 4. CD001925.
65. Hart RG, Pearce LA, Aguilar MI Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
66. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993, 342:1255-1262. EAFT (European Atrial Fibrillation Trial) Study Group.
67. Koudstaal PJ Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2000, 2. CD000186.
68. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 360:2066-2078. The ACTIVE investigators.
69. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edn). Chest 2008, 133(suppl):160S-198S. for the American College of Chest Physicians.
70. Saxena R, Koudstaal PJ Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev 2003, 3. CD000185.
71. Mant J, Hobbs FDR, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007, 370:493-503. for the BAFTA investigators and Midland Research Practices Network (MidReC).
72. Saxena R, Koudstaal PJ Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev 2004, 4. CD000187.
73. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367:1903-1912. The ACTIVE Writing Group on behalf of the ACTIVE investigators.
74. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008, 118:2029-2037. for the ACTIVE W Investigators.
75. Healey JS, Hart RG, Pogue J, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W). Stroke 2008, 39:1482-1486.
76. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008, 1:84-91.
77. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006, 37:1070-1074.
78. Pengo V, Pegoraro C, Cucchini U, Iliceto S Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis 2006, 21:73-77.
79. Eriksson BI, Quinlan DJ, Eikelboom JW Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011, 62:41-57.
80. Weitz JI New oral anticoagulants: a view from the laboratory. Am J Hematol 2012, 87(suppl 1):S133-S136.
81. Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007, 64:292-303.
82. Hankey GJ, Eikelboom JW Dabigatran etexilate-a new oral direct thrombin inhibitor. Circulation 2011, 123:1436-1450.
83. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939- an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005, 61:873-880.
84. Kubitza D, Becka M, Roth A, Mueck W Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008, 24:2757-2765.
85. Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009, 37:1056-1064.
86. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihaemostatic studies. J Thromb Haemost 2008, 6:820-829.
87. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009, 37:74-81.
88. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010, 160:635-641.
89. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011, 123:2363-2372.
90. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012, 43:1511-1517.
91. Uchino K, Hernandez AV Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012, 172:397-402.
92. Eikelboom JW, Weitz JI Anticoagulation therapy: dabigatran and risk of myocardial infarction. Nat Rev Cardiol 2012, 9:260-262.
93. Diener H-C, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010, 9:1157-1163. for the RE-LY study group.
94. Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012, 11:315-322. for the ROCKET AF Steering Committee Investigators.
95. Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012, 11:503-511. for the ARISTOTLE Committees and Investigators.
96. Diener H-C, Eikelboom J, Connolly SJ, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012, 11:225-231. for the AVERROES steering committee and investigators.
97. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012, 110:453-460.
98. Lip GY, Larsen TB, Skjøth F, Rasmussen LH Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012, 60:738-746.
99. Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012, 5:480-486.
100. Harenberg J, Marx S, Diener HC, et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network metaanalysis. Int Angiol 2012, 31:330-339.
101. Mantha S, Ansell J An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012, 108:476-484.
102. Testa L, Agnifili M, Latini RA, et al. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM 2012, 105:949-957.
103. Baker WL, Phung OJ Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012, 5:711-719.
104. Hankey GJ, Eikelboom JW What do the results of the PRoFESS trial teach us?. Lancet Neurol 2008, 7:860-862.
105. Beasley BN, Unger EF, Temple R Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011, 364:1788-1790.
106. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012, 107:838-847.
107. Eikelboom JW, Quinlan DJ, Connolly SJ, Hart RG, Yusuf S Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation. J Thromb Haemost 2012, 10:966-968.
108. Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN). Am Heart J 2012, 163:931. 37.e1.
109. Bokura H, Saika R, Yamaguchi T, et al. Microbleeds are associated with subsequent hemorrhagic and ischemic stroke in healthy elderly individuals. Stroke 2011, 42:1867-1871.
110. Ho PM, Bryson CL, Rumsfeld JS Medication adherence: its importance in cardiovascular outcomes. Circulation 2009, 119:3028-3035.
111. Doggrell SA Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help?. Drugs Aging 2010, 27:239-254.
112. Bangalore S, Kumar S, Wetterslev J, et al. Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. Arch Neurol 2011, 68:172-184.
113. Freyburger G, Macouillard G, Labrouche S, Sztark F Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011, 127:457-465.
114. Tripodi A, Chantarangkul V, Guinet C, et al. The international normalized ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 2011, 9:226-228.
115. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103:815-825.
116. Samama MM, Guinet C Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011, 49:761-772.
117. Miesbach W, Seifried E New direct oral anticoagulants-current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012, 108:625-632.
118. Van Ryn J, Standier J, Liesenfeld K-H, et al. Dabigatran etexilate- a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103:1116-1127.
119. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Thromb Haemost 2012, 107:985-997.
120. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103:815-825.
121. Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010, 104:1078-1079.
122. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010, 32:673-679.
123. Tripodi A Measuring the anticoagulant effect of direct factor Xa inhibitors: is the anti-Xa assay preferable to the prothrombin time test?. Thromb Haemost 2011, 105:735-736.
124. Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007, 38:1655-1711. for the American Heart Association, American Stroke Association Stroke CouncilAmerican Stroke Association Stroke Council, Clinical Cardiology CouncilClinical Cardiology Council, Cardiovascular Radiology and Intervention CouncilCardiovascular Radiology and Intervention Council, Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working GroupsAtherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups.
125. Dempfle C-E, Hennerici MG Fibrinolytic treatment of acute ischemic stroke for patients on new oral anticoagulant drugs. Cerebrovasc Dis 2011, 32:616-619.
126. Brouns R, Van Hooff RJ, De Smedt A, et al. Acute stroke management in patients taking dabigatran. CNS Neurosci Ther 2012, 18:616-622.
127. Alberts MJ, Bernstein RA, Naccarelli GV, Garcia DA Using dabigatran in patients with stroke: a practical guide for clinicians. Stroke 2012, 43:271-279.
128. Baker WL, Colby JA, Tongbram V, et al. Neurothrombectomy devices for the treatment of acute ischemic stroke: state of the evidence. Ann Intern Med 2011, 154:243-252.
129. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012, 87(suppl 1):S141-S145.
130. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011, 42:3594-3599.
131. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
132. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012, 108:217-224.
133. Godier A, Miclot A, Le Bonniec B, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012, 116:94-102.
134. Levi M, Levy JH, Andersen HF, et al. Safety of recombinant activated factor VII in randomized clinical trials. N Eng J Med 2010, 363:1791-1800.
135. van Ryn J, Litzenburger T, Waterman A, et al. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models (abstract). J Am Coll Cardiol 2011, 57(suppl 1):E1130.
136. Kamel H, Johnston SC, Easton JD, Kim AS Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2012, 43:881-883.
137. Kansal AR, Sorensen SV, Gani R, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 2012, 98:573-578.
138. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011, 154:1-11.
139. Shah SV, Gage BF Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011, 123:2562-2570.
140. Pink J, Lane S, Pirmohamed M, Hughes DA Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 2011, 343:d6333.
141. Kamel H, Easton JD, Johnston S, Kim AS Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology 2012, 79:1428-1434.